Multiple System Atrophy Market Seen Soaring 4% Growth to Reach USD 180 Million by 2030, Projects Univdatos Market Insights
- Vikas Kumar
- November 24, 2023
- HEALTHCARE, NEWS
- Multiple System Atrophy Market Analysis, Multiple System Atrophy Market Forecast, Multiple System Atrophy Market Growth, Multiple System Atrophy Market Outlook, Multiple System Atrophy Market Share, Multiple System Atrophy Market Size, Multiple System Atrophy Market Trends
- 0 Comments
According to a new report by Univdatos Market Insights, Multiple System Atrophy Market, is expected to reach USD 180 Million in 2030 by growing at a CAGR of 4%. Multiple System Atrophy, known as the deadly neurogenetic disorder, occurs due to deterioration or atrophy of specific regions of the brain. Patients generally loose balance control and experience stiffness in the body. Diagnosis for multiple system atrophy often begins when a patient experiences slowness in moment and tremors followed by digestive, urinary and excretion difficulties. These non-specific symptoms call for further investigation, pushing medical professionals to rule out possibility of having multiple system atrophy using diagnostic tools. Techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET) often provide the first glimpse of abnormalities in specific regions of brain. However, there are no exact diagnosis nor treatment methods available for easier diagnosis or permanent cure of the multiple system atrophy. MRI (magnetic resonance imaging) scans and PET (positron emission tomography) scans offer detailed images of the affected area based on the symptoms reported. single photon emission computed tomography (SPECT), tilt table test are the other methods used for confirming multiple system atrophy.
Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=45948
The report suggests that the Rising Research & Development is one of the major factors driving the growth of the multiple system atrophy market during the forthcoming years. Multiple system atrophy is a type of neurogenetic disorder that affects the brain cells in the body. Clinical trials are essential for the development of new treatments for multiple system atrophy, as they provide valuable information on the safety and effectiveness of different treatment options. In recent years, there has been an increasing number of clinical trials focused on multiple system atrophy. For example, Lundbeck pharmaceutical company launched phase 2 to evaluate efficacy of drug Lu AF82422 versus Placebo on patients suffering from MSA in November 2021.
Also, NYU Langone Health tested ampreloxetine which is a new drug for orthostatic hypotension for treatment of multiple system atrophy in October 2021. Pharma companies are also investigating new combinations of treatments and new targeted therapies that may be more effective and have fewer side effects than existing treatments. The increasing number of clinical trials for multiple system atrophy is driving the growth of the market, as it indicates a greater interest in developing new treatments for this disease. Other strategies such as target neuroinflammation, neurotrophic support, mitochondrial dysfunction, and excitotoxicity are also being targeted to bring out an effective treatment of the disease. It also provides hope for patients with multiple system atrophy, as it suggests that there may be more effective treatment options available in the future. Presently, Levodopa is being used as first-line therapy to decrease effects of multiple system atrophy.
Fig1: Clinical Trials in Multiple System Atrophy by Phase, 2023
Apart from this, growing technological advancements including big data analytics, the internet of things, artificial intelligence, and virtual reality, amongst others in multiple system atrophy market will also have a positive impact on the market’s growth during the forecast period. One such advancement was proposed by the Movement Disorder Society in 2022 about neuroimaging, which introduces artificial intelligence (AI), machine learning (ML), and deep learning to potentially improve diagnostic accuracy of nerve cells. Another such advancement is the use of targeted therapies, which are designed to specifically target the nerve cells while minimizing damage to healthy cells. Alpha-synuclein which abnormally builds-up in brain cells is the reason behind occurrence of this disorder. This substance is a therapeutic target in ongoing trial and treatment methods. Technological advancements also include immunotherapy therapy against mesenchymal stem cell therapies and serotonin-targeted therapies, they are believed to affect several aspects of the disease, including neuroinflammation as well. This approach has led to improved outcomes for patients with multiple system atrophy and has helped to reduce the side effects associated with traditional treatments.
Artificial Intelligence and Next generation sequencing can prove to be a boon for MSA patients
There is no appropriate diagnostic method for detection of multiple system atrophy. In this situation AI and NGS can prove to be boon for MSA patients. AI would not only help in detection but would also help in finding effective treatment methods by finding the reason behind accumulation of alpha- synuclein. Artificial Intelligence and Machine Learning are gaining traction in the multiple system atrophy market:
Precision Medicine: Artificial Intelligence, as part of the broader shift towards precision medicine, can be used to design medications to attack specific genetic or molecular abnormalities in nerve cells, potentially making them healthier cells.
Unmet Need: Multiple system atrophy is often resistant to traditional methods of treatment. This makes Artificial Intelligence, which may be effective on pairing with Next-generation sequencing to find personalized and permanent cure for this disease.
Genomic Insights: Advances in next generation sequencing technologies have led to increased possibilities of finding reasons that drive multiple system atrophy, providing potential targets for new therapies.
Patient Survival and Quality of Life: Next generation sequencing is often more precisely directed at genomic level, which will help us in finding route cause of the disease. It may offer improved survival rates and better quality of life for patients by causing fewer side effects compared to traditional therapies.
Click here to view the Report Description & TOC https://univdatos.com/report/multiple-system-atrophy-market/
Conclusion
The global multiple system atrophy market is a rapidly growing field, with advancements in technology and treatments leading to improved outcomes for patients. Multiple system atrophy is a type of neurogenerative disorder that affects the nerve cells in the brain, and it is sporadic in occurrence. The global multiple system atrophy market is expected to continue to grow in the coming years, as new treatments are developed, and more patients are diagnosed with the disease. As a result, there is a growing demand for skilled professionals in the field of neurology, including neurologists, brain therapists, and researchers. Overall, the global multiple system atrophy market represents a significant opportunity for companies and professionals in the field of neurology. With continued research and development, it is likely that even more effective and personalized treatments will become available in the future, leading to improved outcomes for patients with multiple system atrophy.
Related Posts
